• CMR Surgical

  Participated · Series C · Sep 2019

  CMR Surgical is a global medical devices company headquartered in Cambridge, United Kingdom, that develops the Versius Surgical Robotic System, a soft-tissue surgical robot for minimal access procedures. Its core product, Versius, is described as a versatile, adaptable, next-generation digitally driven surgical robot and was recently granted FDA marketing authorization for use in cholecystectomy. The company says it collaborates with surgical teams and hospital partners to make robotic minimal access surgery more accessible and affordable. Founded in 2014, CMR is a private limited company backed by an international shareholder base. Management plans to scale operations and accelerate commercial expansion, with a major focus on launching Versius in the United States. Financially, CMR recently closed a financing round of more than $200 million. CMR Surgical develops the Versius® surgical robotic system and is led by CEO Supratim Bose. The system gained CE approval in 2019 and more than 140 systems have been installed in hospitals worldwide. Versius has been used to perform more than 15,000 procedures across seven surgical specialties and over 130 procedure types. Installations span the UK, Europe, Latin America, the Middle East, Asia and Africa and include major research hospitals. The company intends to use the new funding for continued product innovation, new technological developments, and further commercialisation in key existing and new geographies. CMR Surgical develops Versius, a next-generation, portable and modular surgical robotic system designed for minimally invasive procedures. Versius reproduces natural human arm movement, offers 3D HD vision, fully articulated small instruments and an open surgeon console to improve ergonomics and team communication. The system is designed to fit into existing operating-room workflows and can be configured with only the number of arms required for a given procedure. CMR is building a digital ecosystem around Versius, including Versius Connect, Versius Trainer and a clinical registry to capture data for continuous learning. The company emphasizes affordability and global accessibility and has launched Versius in Europe, Australia, India and the Middle East. CMR was founded in 2014 and is headquartered in Cambridge, United Kingdom. CMR Surgical develops, manufactures and markets Versius, a modular surgical robotic system for minimal access surgery that offers 3D HD vision, instrument control and ergonomic working positions. Versius is designed to biomimic the human arm, providing surgeons with enhanced dexterity and precision. The company received the European CE Mark for the system in March 2019 and now has offices on four continents. CMR Surgical employs around 400 people and is led by CEO Martin Frost. The company intends to use new funding to scale global deliveries of Versius while supporting continued R&D, manufacturing and expansion. The business is actively commercializing its system to hospitals worldwide. CMR Surgical is developing a universal robotic system called Versius for minimal access surgery, intended for use across a range of surgical specialties. Led by CEO Martin Frost, the company is conducting preclinical trials that demonstrate Versius can perform upper gastrointestinal, gynaecological, colorectal and renal surgery. CMR will use the Series B proceeds to prepare the Versius system for planned commercialisation. Planned activities include completion of validation studies to support regulatory approval processes in Europe and the USA. The company also intends to fund international expansion and commercial scale-up. The company is based in Cambridge, UK.

No current team members are available.